Original Article

Comorbidity Is a Competing Factor for Disease Recurrence Postnephrectomy

Objective: There is a relation between tumor stage and grade with the risk of cancer recurrence in patients undergoing surgical treatment for kidney cancer. The association of patient comorbidity with disease recurrence is less well characterized. The objective of this study was to explore the association between comorbidity and the…

Posted in: Charlson Comorbidity Index 3 comorbidity 8 renal cell carcinoma 6 renal mass 2

Case Report

A Case of Tubulocystic Carcinoma Simultaneously Occurring with Clear Cell Type Renal Cell Carcinoma and Micropapillary Urothelial Carcinoma of Bladder

Abstract:The coexistence of multiple and synchronous primary neoplasms in the genitourinary system has rarely been described in the literature. To our knowledge, this is the first report of a very rare tumor, a “tubulocystic carcinoma,” simultaneously occurring with micropapillary urothelial carcinoma in the bladder and clear cell type renal cell…

Posted in: renal cell carcinoma 6

Case Report

Multiple Painful Cutaneous Facial Papules

A 21-year-old female with linear, flesh-colored papules on her face was diagnosed with cutaneous piloleiomyoma. Important associations for physicians to be aware of include uterine leiomyomas, leiomyosarcomas, and renal cell carcinoma. Mutations for this syndrome have been mapped to the fumarate hydratase gene.

Posted in: renal cell carcinoma 6

Case Report

A Case of Paraneoplastic Cerebellar Ataxia Secondary to Renal Cell Carcinoma

A 64-year-old female patient presented with acute cerebellar ataxia. After ruling out vascular, infectious, metastatic, demyelinating, and medication etiologies, a paraneoplastic origin for her illness was determined. A renal mass was discovered and found to be renal cell carcinoma. Her symptoms resolved after a radical nephrectomy. Physicians should consider the…

Posted in: renal cell carcinoma 6 renal mass 2

Case Report

Acute Pancreatitis Associated with Sorafenib

Since its FDA approval in December 2005, sorafenib (Nexavar®) has been in use for the treatment of metastatic renal cell carcinoma. With this increased use have come reports of adverse effects of sorafenib. To the best of the authors’ knowledge, they are the first to describe an 80-year-old Asian male…

Posted in: pancreatitis 16 renal cell carcinoma 6 sorafenib 2 tyrosine kinase inhibitor 2

Case Report

Yellow Skin Discoloration Associated with Sorafenib Use for Treatment of Metastatic Renal Cell Carcinoma

This report describes a patient with metastatic kidney cancer who developed a deep yellow skin discoloration while on therapy with the oral multitargeted tyrosine kinase inhibitor (TKI), sorafenib. A significant hand-foot syndrome, featuring acral skin desquamation and tender erythema at pressure points, was also present. A thorough clinicolaboratory investigation did…

Posted in: hand-foot syndrome 2 renal cell carcinoma 6 sorafenib 2
SMA Menu